Company
BioEclipse
Proprietary Allogeneic, Off-the-shelf, Technology Designed To Destroy Cancer Cells While Enabling The Patient's Own Immune System To Recognize, Attack And Clear Cancer
Also known as BioEclipse Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary platform technology to develop the next generation of immuno-oncology therapeutics.
Funding snapshot
- Total raised
- $10.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant, $8M2022-04-26
Funding rounds
- Grant
- $8M2022-04-26, Company stated
- Round, 2019
- $10.1M2019-06-07, SEC form D sold, 13 investors
Products
- Other
- CRX100
- Other
- CRX200
Loading relationship preview